nightstar THERAPEUTICS

Sep 2012
Identification of retinal gene therapy as a core area of interest where a company can get built

Sep 2012 – Mar 2013
Broad sector wide research, including meetings and discussions with leaders in the field

Nov 2012
First meeting with Robert MacLaren

Mar 2013 – Dec 2013
Identification of executives and consultants to enable fast start

Jan 2014
Syncona founds the company with Series A financing of £12m; Syncona CIO, Chris Hollowood is appointed Chairman

Jan 2015
David Fellows appointed as Chief Executive

Syncona approaches Oxford to license further programmes from Robert's group. Syncona commissions IP counsel to ensure best IP strategy for those programmes in parallel with negotiation

Syncona initiates financing on behalf of company and market to leading US funds

Nov 2015
Series B financing of $35m; Syncona invests $10m, NEA $25m in conjunction with execution of licence for further programmes

Mar 2017
Syncona identifies Stargardt's as an attractive programme given derisking data elsewhere in the gene therapy field

Jul 2017
Series C financing of $45m; Syncona invests $12.5m

Sep 2017
$76m listing on NASDAQ; Syncona invests $14m

Nov 2017
NITE execute further licence with Oxford for Stargardt programme

Mar 2018
Initiates Pivotal trial in first programme in Choroideremia

Jun 2018
Receives RMAT designation in first programme in Choroideremia

Sep 2018
Announces positive proof-of-concept data in second programme in XLRP

Follow-on financing of $83m with Syncona investing $18m

Nov 2018
Planned initiation of phase 2/3 study in second programme in XLRP

Mar 2019
Agreement to be acquired by Biogen for $877m; £256m cash return for Syncona, a 4.5x multiple of original cost and 72% IRR

2012 2013 2014 2015 2016 2017 2018 2019

Found

- Technical Diligence
- Business Model
- IP Diligence
- Terms & Legals

Build

- Platform Development
- Pre-Clinical Pipeline
- Clinical Pipeline
- Fully operational

Fund

Fund